OncoMatch/Clinical Trials/NCT04822337
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Official title: A Phase I/II Study of Carfilzomib, Lenalidomide, Dexamethasone and the Anti-B-Cell Maturation Antigen (BCMA) Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma
Is NCT04822337 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin for multiple myeloma.
Treatment: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin — This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Multiple Myeloma
Biomarker criteria
Required: TP53 mutation
High-risk disease at diagnosis, as defined by at least one of the following: ... del(17p)* and/or TP53 mutation
Required: IGH t(4;14)
High-risk disease at diagnosis, as defined by at least one of the following: ... t(4;14), t(14;16) or t(14;20)
Required: IGH t(14;16)
High-risk disease at diagnosis, as defined by at least one of the following: ... t(4;14), t(14;16) or t(14;20)
Required: IGH t(14;20)
High-risk disease at diagnosis, as defined by at least one of the following: ... t(4;14), t(14;16) or t(14;20)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — Relapsed or Relapsed/Refractory MM (Phase I)
Subjects with Relapsed or Relapsed/Refractory MM who have had at least 1 line of prior therapy
Cannot have received: lenalidomide (lenalidomide)
Exception: subject must not have progressed on full dose lenalidomide previously (25 mg on days 1-21 of a 28-day cycle or its dosing equivalent based on renal function at the time of progression)
Subject must have not progressed on full dose lenalidomide previously
Cannot have received: carfilzomib (carfilzomib)
Exception: discontinuation due to treatment toxicity
Discontinuation of prior carfilzomib due to treatment toxicity
Cannot have received: lenalidomide (lenalidomide)
Exception: discontinuation due to treatment toxicity
Discontinuation of prior lenalidomide due to treatment toxicity
Cannot have received: dexamethasone (dexamethasone)
Exception: discontinuation due to treatment toxicity
Discontinuation of prior dexamethasone due to treatment toxicity
Lab requirements
Blood counts
Hematologic lab results within parameters noted in Table 3.2.1
Kidney function
Liver function
Cardiac function
LVEF > 40% by ECHO, cardiac MRI or MUGA; no significant cardiac disease (see exclusion criteria 8)
Demonstrate adequate organ function; Adequate cardiac function as defined by a greater than 40% left ventricular ejection fraction (LVEF) by ECHO, cardiac MRI or MUGA
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Levine Cancer Institute · Charlotte, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04822337 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior lenalidomide, carfilzomib, lenalidomide disqualifies patients from enrollment.
Does this trial require TP53?
Yes, TP53 mutation is a required biomarker for enrollment.
Does this trial require IGH?
Yes, IGH t(4;14) is a required biomarker for enrollment.
Does this trial require IGH?
Yes, IGH t(14;16) is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages